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Abstract
Background: Neuroinflammation involves the activation of glial cells in neurodegenerative diseases such as
Alzheimer’s disease (AD). Plasmalogens (Pls) are glycerophospholipids constituting cellular membranes and play
significant roles in membrane fluidity and cellular processes such as vesicular fusion and signal transduction.
Methods: In this study the preventive effects of Pls on systemic lipopolysaccharide (LPS)-induced
neuroinflammation were investigated using immunohistochemistry, real-time PCR methods and analysis of brain
glycerophospholipid levels in adult mice.
Results: Intraperitoneal (i.p.) injections of LPS (250 μg/kg) for seven days resulted in increases in the number of
Iba-1-positive microglia and glial fibrillary acidic protein (GFAP)-positive astrocytes in the prefrontal cortex (PFC) and
hippocampus accompanied by the enhanced expression of IL-1β and TNF-α mRNAs. In addition, β-amyloid
(Aβ3–16)-positive neurons appeared in the PFC and hippocampus of LPS-injected animals. The co-administration of
Pls (i.p., 20 mg/kg) after daily LPS injections significantly attenuated both the activation of glial cells and the
accumulation of Aβ proteins. Finally, the amount of Pls in the PFC and hippocampus decreased following the LPS
injections and this reduction was suppressed by co-treatment with Pls.
Conclusions: These findings suggest that Pls have anti-neuroinflammatory and anti-amyloidogenic effects, thereby
indicating the preventive or therapeutic application of Pls against AD.
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Background
It has been demonstrated in mice and rats that the sys-
temic administration of lipopolysaccharide (LPS) and
polyriboinosinic:polyribocytidylic acid (poly I:C), ligands
for toll-like receptor (TLR) 4 and TLR 3, respectively, in-
duce neuroinflammation in the central nervous system
(CNS), thus leading to neurodegeneration, the suppres-
sion of neurogenesis and the impairment of cognitive
behavior [1-3]. One of the possible mechanisms of neu-
roinflammation may be the production of β-amyloid
proteins (Aβ). For example, a single intraperitoneal (i.p.)
injection of LPS increases the activity of β-secretase, a
key rate-limiting enzyme that initiates Aβ formation,
and the concentration of brain Aβ1–42 in adult but not
young mice [1]. Furthermore, the intracellular accumula-
tion of Aβ1–42 in hippocampal pyramidal neurons fol-
lowing daily injections of LPS for seven days has been
immunohistochemically demonstrated [1]. Although the
precise mechanisms underlying LPS-induced amyloido-
genesis have not yet been determined, it is likely that
proinflammatory cytokines such as IL-1β, TNF-α, IFN-γ,
and reactive oxygen/nitrogen species (ROS/RNS)
released from activated glial cells play significant roles in
Aβ formation, which are suppressed by NSAIDs through
the activation of peroxisome proliferator-activated recep-
tor-γ (PPAR-γ) [4-6].
Plasmalogens (Pls) are unique glycerophospholipids that
contain a vinyl ether bond at the sn-1 position of the
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glycerol moiety. They are found in all mammalian tissues,
especially in the heart and brain, in which ethanolamine
Pls (PlsEtn) are much more abundant than choline Pls
(PlsCho) [7]. Pls release either docosahexaenoic acid
(DHA) or arachidonic acid (ARA) from the sn-2 position
through the activation of Pls-selective phospholipase A2
(Pls-PLA2) [8,9]. Pls are not only structural membrane
components and reservoirs for second messengers, but
they are also involved in membrane fusion, ion transport
and cholesterol efflux [7]. In addition, the vinyl ether bond
at the sn-1 position makes Pls more susceptible to oxida-
tive stress than corresponding ester bonded glyceropho-
spholipids, which act as antioxidants and protect cells
from oxidative stress [10-13].
It has been shown that patients suffering from Alzhei-
mer’s disease (AD) have reduced PlsEtn levels in the cor-
tex and hippocampus [14-16]. The reduction of PlsEtn
levels seems to be specific since other neurodegenerative
diseases such as Huntington’s and Parkinson’s do not
show decreases in corresponding affected brain regions
(the caudate nucleus and the substantia nigra, respect-
ively) [7,14,17]. Furthermore, circulating PlsEtn levels
are also decreased depending on the severity of dementia
[18,19]. It has been suggested that deficiencies of PlsEtn
may lead to increases in the vulnerability of neural
membranes to oxidative stress, destabilization of mem-
branes, impairment of muscarinic cholinergic signals
and abnormal amyloid precursor processing [7,17,20].
Although Pls are considered to be involved in the
pathology of AD, the influence of Pls on Aβ accumula-
tion has not been examined, probably due to the diffi-
culty of extracting massive amounts of intact Pls.
Recently, we developed a new method for preparing
highly pure Pls [21], which enabled us to investigate this
issue. In the present study, in order to elucidate the
anti-neuroinflammatory/anti-amyloidogenic actions of
Pls, we investigated the effects of co-administered Pls on
the systemic LPS-induced changes in the morphology of
glial cells, the expression of cytokines, the accumulation
of Aβ and the levels of Pls in the prefrontal cortex (PFC)
and hippocampus of adult mice.
Methods
All experimental procedures involving the use of animals
were approved by the Ethics Committee on Animal
Experiments at Kyushu University and were in accord-
ance with the Guiding Principles for the Care and Use of
Animals of the Physiological Society of Japan. All efforts
were made to minimize animal suffering and the number
of animals used in the study.
Animals
Male C57/6J mice weighing 32 to 37 g (10 months old)
were used in all experiments. The animals were housed
five per cage at a temperature of 22 ± 2°C with 12 hour
light/12 hour dark cycles (lights on at 8:00) with free ac-
cess to laboratory food and water. The mice were ran-
domly divided into four groups: control (Con), LPS,
LPS + Pls and Pls. LPS (Sigma-Aldrich, St. Louis, MO,
USA) was dissolved in saline, while the Pls were dis-
solved in corn oil then sonicated to ensure complete
solubilization. The LPS group received an i.p. injection
of LPS (250 μg/kg) followed by corn oil in the morning
(9:00 to 10:00) daily for seven days (days 1 to 7). The
LPS + Pls group was treated with LPS followed by Pls
(20 mg/kg) for seven days, while the Pls group was
injected with saline and Pls. The Con group was given
saline and corn oil for seven days. All animals were
sacrificed on day 8. The body weights were measured in
the morning before injection on day 1 to day 8.
Pl preparation
The Pls used in the present study were prepared from
chicken breast muscle using a previously reported
method [21]. A HPLC used for phospholipid separation
[22] indicated that the purified Pls consisted of 47.6%
PlsEtn, 49.3% PlsCho, 2.4% sphingomyelin (SM) and
0.5% other phospholipids. The composition of fatty acids
of PlsEtn and PlsCho was analyzed using the previously
described HPLC method [21], as shown in Table 1.
Immunohistochemistry and immunofluorescence
The mice were deeply anesthetized with pentobarbital
(50 mg/kg) and transcardially perfused with PBS fol-
lowed by 4% paraformaldehyde. For each animal, the
brain was removed, post-fixed for 24 hours and then
transferred successively to 20% and 30% sucrose solu-
tions. Subsequently, the brains were frozen on a cold
stage and sliced into 30 μm thicknesses using a cryostat.
The sections were permeabilized with 0.3% Triton-X 100
(Sigma-Aldrich) in PBS for 15 minutes and blocked in
PBS containing 1% BSA and 5% normal donkey serum
(Jackson ImmunoResearch Lab., West Grove, PA, USA)
Table 1 The fatty acid composition of the PlsEtn and







16:0 (palmitic acid) 3.6 20.5
18:0 (stearic acid) 2.2 12.4
18:1, n-9 (oleic acid) 26.3 20.1
18:2, n-6 (linoleic acid) 4.1 10.1
18:3, n-3 (α-linolenic acid) 7.2 3.8
20:4, n-6 (arachidonic acid, ARA) 24.9 17.2
22:6, n-3 (docosahexaenoic acid, DHA) 18.6 2.3
others 13.2 13.6
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for 60 minutes at room temperature. The sections were
incubated in blocking solution (Block Ace, Dainippon
Pharmaceutical, Osaka, Japan) for 30 minutes at room
temperature and then incubated with rabbit polyclonal
antibodies against Iba-1 (1:10000; Wako Pure Chem.
Indus., Osaka, Japan), which are known to have specific
affinity for microglial Ca2+-binding proteins and are
highly expressed by activated microglia, and anti-glial fi-
brillary acidic proteins (GFAPs, 1:3000; Sigma-Aldrich)
for astrocytes in 10% Block Ace in PBS at 4°C overnight.
Other sections were incubated with polyclonal anti-
bodies against Aβ3–16 (1:1000; ab14220, Abcam, Cam-
bridge, UK) and NeuN (1:1000; Millipore, Billerica, MA,
USA). According to the manufacturer’s instructions,
ab14220s react with all isoforms of mouse and rat Aβ.
The rinsed sections were incubated for six hours with
Alexa Fluor 488 goat anti-rabbit IgG or Alexa Flour 568
goat anti-mouse immunoglobulin G (IgG) (1:1000; Invi-
trogen, Eugene, OR, USA) at room temperature. Every
treatment was followed by washing three times for five
minutes with PBS. The sections were then mounted in
the perma fluor aqueous mounting medium (Thermo
Fisher Scientific, Waltham. MA, USA).
Quantitative analysis of fluorescence intensity
All samples were analyzed with a confocal laser-
scanning microscope (LSM510 Meta; Carl Zeiss, Jena,
Germany). The number of glial cells in 90 to 100 areas
of 200 μm x 200 μm in four slices per brain was counted
and the average number/4 x 104 μm2 was obtained for
each brain.
Real-time PCR
Mice were deeply anaesthetized with pentobarbital and
perfused transcardially with phosphate buffered saline,
then the PFC and hippocampus were removed immedi-
ately. Total RNA was isolated from the samples using
magnetic beads (MagExtractor system; Toyobo, Tokyo,
Japan) after homogenizing the tissues. Primer pairs were
chosen to flank at least one intron. The amount of total
RNA was quantified by measuring the optical density
250 using a Nanodrop spectrophotometer (Nanodrop,
Wilmington, DE, USA). For reverse transcription, 100
ng of total RNA was transferred to the reaction using an
RNA PCR kit (AMV) (Takara Bio Inc., Ootsu, Japan)
and 9-mer random primers. SYBR-Green real-time PCR
(Applied Biosystems, Foster City, CA, USA) was per-
formed on cDNA prepared from each sample using the
THUNDERBIRD SYBR qPCR Mix, ROX reference dye
(Toyobo) and 0.5 mM of each primer. The data were
analyzed using 7500 System software v2.0 (Applied Bio-
systems). All values of cytokines were normalized to the
corresponding β-actin concentration obtained using the
same method. The sequences of primers were follows:
IL-1β, sense; 50- CTCCATGAGCTTTGTACAAGG -30,
antisense; 50- TGCTGATGTACCAGTTGGGG -30;
TNF-α, sense; 50- CCACCACGCTCTTCTGTCTAC -30,
antisense; 50- TGGGCTACAGGCTTGTCACT -30 β-
actin, sense; 50- TTGCTGACAGGATGCAGAAGGAG
-30, antisense; 50- GTGGACAGTGAGGCCAGGAT -30.
The predicted sizes of the PCR products were 245 bp for
IL-1β, 196 bp for TNF-α, and 127 bp for β-actin mRNA.
Measurement of the Pl levels in the PFC and
hippocampus
Mice were deeply anesthetized with pentobarbital (50
mg/kg) and transcardially perfused with sterile PBS. For
each animal, the brain was removed and the PFC and
hippocampus were dissected in a dish filled with ice-
cold PBS. The samples (300 mg to 500 mg) were stored
at −80°C until Pl measurement. Total lipids were
extracted using the method of Folch and coworkers [23],
and the relative composition of phospholipid classes, in-
cluding Pls, was measured as previously reported [22].
Statistical analysis
The results are expressed as the mean ± SEM. The body
weights (BWs), numbers of Iba-1+ and GFAP+ cells and
amounts of mRNAs were compared using one-way ana-
lysis of variance (ANOVA) followed by post hoc
(Scheffe’s) test. Changes in the PlsEtn levels and the ratio
of PlsEtn/Phosphatidyl Etn (PEtn) determined after LPS
and Pl injection were evaluated using the non-
parametric Kruskal-Wallis test followed by the Steel test
for multiple comparisons. Values of P <0.05 were con-
sidered to be statistically significant.
Results
Body weight changes after LPS and Pls
The BWs of the mice in the LPS group started to
decrease on day 2 and showed significant differences
between groups on day 4 that lasted until day 8 (day 4:
F(3,28) = 7.1, day 5: F(3,28) = 8.1, day 6: F(3,28) = 6.0, day
7: F(3,28) = 9.0 and day 8: F(3,28) = 9.4, P <0.01, respect-
ively, each group, n = 8). The post hoc test indicated
that the BWs of the LPS group were different from
those of the control (Con) group (day 4, 5, 7 and 8,
P <0.05) and the Pls group (from day 4 to 8, P <0.01).
However, the LPS + Pls group showed no significant
differences between either the Con or Pls group in
terms of BW at any point (Figure 1).
Suppression of glial activation by Pls
As shown in Figure 2Aa, the Con group that received sa-
line and corn oil for seven days showed typical features
of Iba-1-positive (green) resting microglia with small
and compact soma bearing ramified processes (a’) in the
PFC. GFAP was immunostained with weak fluorescence
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(red) in astrocytes (b). However, the i.p. administration
of LPS (250 μg/kg/day) for seven days (LPS group, sec-
ond row) resulted in neuroinflammation showing
increased numbers of Iba-1-positive microglia and in-
tense immunoreactivity (d) with activated phenotypes
of marked cellular hypertrophy and retraction of cyto-
plasmic processes (d’). GFAP-positive astrocytes also
increased in number and intensity (e). As shown in
Figure 2Ag and h, the increases in the number of acti-
vated microglia and astrocytes in the PFC were sup-
pressed by i.p. administration of LPS and Pls (20 mg/
kg) (LPS + Pls group). Iba-1-positive microglia and
GFAP-positive astrocytes did not merge with each
other in all groups (c, f, i, and l). Figure 2B shows a
summary of the LPS-induced increases in the number
of glial cells and the suppression of this increase by
Pls (each bar, n = 8). The number of microglia (left)
and astrocytes (right) significantly increased following
LPS injection (F(3,28) = 38.4, P <0.01; F(3,28) = 45.8,
P <0.01, respectively). The multiple-range test indicated
that the numbers of microglia and astrocytes in the
LPS group were different from those in the Con, Pls, and
LPS + Pls groups (Scheffe’s test, P <0.01, respectively),
while the LPS + Pls group did not differ from the Con
or Pls groups for either microglia or astrocytes.
In the CA1 region of the hippocampus, both Iba-1-
positive microglia and GFAP-positive astrocytes
increased in number in the LPS group (Figure 3Ad and
e) compared with that observed in the control group (a
and b). Similar to that observed in the PFC, the
increases in the number of activated glial cells were atte-
nuated following the administration of Pls (g and h). As
shown in Figure 3B, the statistical analysis indicated
significant differences in the numbers of microglia
(left: F(3,28) = 10.7, P <0.01) and astrocytes (right:
F(3,28) = 11.2, P <0.01) between the groups (each bar,
n = 8). LPS injection increased the numbers of micro-
glia (left: P <0.01) and astrocytes (right: P <0.01). The
increases were significantly suppressed by Pls to the
levels of microglia and astrocytes observed in the Con
and Pls groups (LPS + Pls group, P <0.05, respectively).
As shown in Figure 4A, the dentate gyrus (DG) of the
hippocampus also demonstrated LPS-induced increases
in the number and intensity of immunostaining for Iba-
1 in microglia (d) and GFAP in astrocytes (e) compared
with that observed in the Con group (a and b). These
increases were suppressed by simultaneous injection of
Pls (g and f, respectively). One-way ANOVA indicated
significant differences in the numbers of microglia
(Figure 4B, left: F(3,28) = 41.4, P <0.01) and astrocytes
(right: F(3,28) = 11.5, P <0.01) between the groups (each
bar, n = 8). The differences in the numbers of microglia
and astrocytes in the Con and Pls groups (P <0.01)
and the LPS + Pls group were significant (P <0.01 and
P <0.05, respectively).
Suppression of LPS-induced increases in cytokine mRNA
by Pls
As shown in Figure 5A, the relative amounts of mRNAs
for IL-1β (left) and TNF-α (right) in the PFC were sig-
nificantly different (ANOVA test, F(3,16) = 19.3, P <0.01,
and F(3,16) = 14.9, P <0.01, respectively) between the
groups (each bar, n = 5). The post hoc test indicated that
the levels of both IL-1β and TNF-α mRNAs in the LPS
group were significantly higher than those observed in
the other groups (Scheffe’s test, P <0.01, respectively),
while the levels in the LPS + Pls group were not different
from those observed in the Con and Pls groups, suggest-
ing that Pls have a suppressive effect on LPS-induced
cytokine expression (Figure 5A).
Similar to the findings observed in the PFC, both cyto-
kine mRNAs increased in the hippocampus in the LPS
group (left: IL-1β, F(3,16) = 10.1, P <0.01; right: TNF-α,
F(3,16) = 17.7, P <0.01) in comparison to that observed
in the other three groups (Figure 5 B, P <0.01, respect-
ively; each bar, n = 5).
Suppression of LPS-induced Aβ accumulation by Pls
The presence of LPS-induced amyloidogenesis in the
PFC and hippocampus following LPS injection was
investigated. As shown in Figure 6, a weak fluorescence
for Aβ3–16 immunoreactivity (green) in the PFC of the
control group (Con, b) was apparently increased in the
LPS group (e). The increase in Aβ3–16 immunoreactivity
was attenuated in the LPS + Pls group (h). Neurons in
the cortex were stained with NeuN (red, a, d and g), and
most of the Aβ3–16 fluorescence merged with the NeuN














 LPS+Pls   Pls
**
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Figure 1 Body weight (BW) changes after LPS/Pls
administration. BW was measured immediately prior to injection
on days 1 to 7 and on day 8 before sacrifice. Filled circle: Con group;
open circle: Pls group; filled triangle: LPS group; and open rectangle:
LPS + Pls group. Each group, n = 8, **, P <0.1, LPS versus Pls group;
#, P <0.05 and ##, P <0.01, LPS versus Con group. Con, control; LPS,
lipopolysaccharide; Pls, plasmalogens.
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immunoreactivity, indicating intracellular localization of
Aβ (yellow in f ).
Accumulations of Aβ were also observed in the CA1
region of the hippocampus in the LPS group (Figure 7,
e). Similar to that observed in the PFC, enhanced Aβ3–16
immunoreactivity was markedly attenuated by Pl admin-
istration (LPS + Pls group, h). Again, the presence of
intracellular accumulation of Aβ in the pyramidal neu-
rons was detected using double staining for Aβ3–16 and






































































Figure 2 Activation of glial cells in the murine PFC following LPS injection (i.p.) performed on seven consecutive days and suppression
by Pls applied immediately after each LPS injection. A, Iba-1-positive microglia (green) and GFAP-positive astrocytes (red). The number and
intensity of immunoreactivity of microglia increased after LPS treatment (d) with hypertrophy (d’) compared with that observed in the Con group
(a and a’) and was suppressed by application of Pls (g and g’). The Pls group (j and j’) showed no differences from the Con group. GFAP-positive
astrocytes also demonstrated increases in number and intensity due to LPS and suppression by Pls (middle column). Iba-1 and GFAP
immunostaining did not merge with each other (f). Scale bar: low magnification, 100 μm, and high magnification, 20 μm. B, A summary of
LPS-induced increases in the numbers of microglia (left) and astrocytes (right) and suppression by Pls (each bar, n = 8). **, P <0.01, respectively.
Con, control; GFAP, glial fibrillary acidic protein; LPS, lipopolysaccharide; PFC, prefrontal cortex; Pls, plasmalogens.
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Changes in the Pl levels in the brain after LPS and Pl
treatment
As shown in Table 2, the levels of PlsEtn were much
higher than those of PlsCho both in the PFC and the
hippocampus, although more than 60% of the phospholi-
pids were diacylgylycereophospholipids (PEtn, PCho, PS
and PI). The relative levels of PlsEtn in the PFC signifi-








































































Figure 3 Activation of glial cells following LPS (i.p.) injection and suppression by Pls in the murine CA1 region of the hippocampus. A,
Iba-1-positive microglia (green) and GFAP-positive astrocytes (red). The number and intensity of immunoreactivity of microglia and astrocytes
increased following LPS treatment (d and e) compared with that observed in the Con group (a and b) and was suppressed by Pls (g and h). They
did not merge with each other (right column). PyCL: pyramidal cell layer of the hippocampus. Scale bar: 100 μm. B, A summary of LPS-induced
increases in the numbers of microglia (left) and astrocytes (right) and suppression by Pls (each bar, n = 8). **, P <0.01. Con, control; GFAP, glial
fibrillary acidic protein; i.p., intraperitoneal; LPS, lipopolysaccharide; Pls, plasmalogens.
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Kruskal-Wallis test, χ2(3) = 10.7, P <0.05). A multiple
comparison analysis using the Steel test revealed that
the amount of PlsEtn significantly decreased in the LPS
group in comparison to that observed in the control
group (P <0.05); however, the levels in the LPS + Pls
group were not different from those observed in the
control group (each group: n = 5). Therefore, the ratio of









































































Figure 4 Activation of glial cells following LPS (i.p.) injection and suppression by Pls in the murine dentate gyrus of the hippocampus.
A, Iba-1-positive microglia (green) and GFAP-positive astrocytes (red). The number and intensity of immunoreactivity of microglia and astrocytes
increased following LPS treatment (d and e) compared with that observed in the Con group (a and b) and was suppressed by Pls (g and h). They
did not merge with each other (right column). GCL: granule cell layer. Scale bar: 100 μm. B, A summary of LPS-induced increases in the numbers
of microglia (left) and astrocytes (right) and suppression by Pls (each bar, n = 8). **, P <0.01. Con, control; GFAP, glial fibrillary acidic protein; i.p.,
intraperitoneal; LPS, lipopolysaccharide; Pls, plasmalogens.
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treatment (χ2(3) = 11.5, P <0.01 and Steel test, P <0.05)
and recovered after the i.p. administration of Pls.
As shown in the lower part of Table 2, the relative
levels of PlsEtn in the hippocampus were greater than
those in the PFC in any group (for example, 16.40 ± 0.59
versus 24.18 ± 0.64 in the Con group). Similar to that
observed in the PFC, both the relative levels of PlsEtn
and the PlsEtn/PEtn ratio were significantly reduced by
LPS treatment (Kruskal-Wallis test, χ2(3) = 11.3 and χ2
(3) = 11.4, P <0.01, and Steel test, P <0.05, respectively).
The reduction of the PlsEtn levels in the hippocampus
was also reversed by Pl administration. The levels of the
other phospholipids did not show any significant
changes following all of the treatments.
Discussion
The present study demonstrated that systemic LPS-
induced activation of glial cells, cytokine expression and
accumulation of Aβ in the PFC and hippocampus were
prevented by co-administration of purified Pls in adult
mice. Furthermore, the injection of LPS induced
decreases in the Pl levels in the PFC and hippocampus
that were also suppressed by the administration of Pls.
Mechanisms of LPS-induced accumulation of Aβ
It is well known that the activation of microglia and
astrocytes plays an important role in neuroinflammation
induced by systemic LPS by enhancing the secretion of
cytokines, prostanoids, ROS/RNS and related sub-
stances. In the present study, i.p. injection of LPS for
seven days induced morphological activation and
increased the number of glial cells in the PFC and
hippocampus (Figures 2–4). The amounts of IL-1β
and TNF-α mRNAs, which are considered to be
derived primarily from glial cells, also increased follow-
ing LPS injection (Figure 5). Furthermore, LPS injection
resulted in the intracellular accumulation of Aβ proteins
in both regions (Figures 6 and 7). It has been reported
that i.p. injection of LPS induces deficits in spatial
learning in mice [24,25] that may be due to the en-
hancement of Aβ generation in the hippocampus [1].
It is known that β-secretase is involved in amyloido-
genic processing of amyloid precursor proteins at the
first step, while γ-secretase yields Aβ isoforms such as
the more prevalent Aβ40 and aggregation-prone Aβ42 at
the last step [26]. It has been recently shown that the ac-
tivities of β- and γ-secretase are increased in the cortex
and hippocampus following systemic injection of LPS
[1]. It is possible that microglia play important roles in
this phenomenon since proinflammatory cytokines, as
well as ROS/RNS, released from activated microglia aug-
ment Aβ formation by upregulating β-secretase mRNA
and enzymatic activity [5,27]. Microglia are activated fur-
ther through receptors for advanced glycation end pro-
ducts (RAGE), which bind to Aβ and induce
phagocytosis of Aβ, thereby amplifying the generation of
ROS/RNS and cytokines [26].
Changes in the Pl levels during neuroinflammation
In addition to observing the activation of glial cells and
Aβ accumulation, we found that the Pl levels in the PFC
and hippocampus decreased following LPS administra-
tion (Table 2). It is possible that the decreases in the
amount of Pls during neuroinflammation are due to the
anti-oxidant properties of Pls. It has been shown that
the Pl-specific vinyl ether bond at the sn-1 of the gly-
cerol backbone is targeted by a variety of oxidants, in-
cluding ROS/RNS [10,11,13], and oxidative stress
preferentially oxidizes PlsEtn over phosphatidyl ethano-
lamine (PEtn) [28,29], resulting in the disruption of ves-
icular fusion in the synaptosomes and the decrease in
acetylcholine release [30]. This may at least partly ex-
plain why AD patients show decreases in Pl levels in the
brain [14-16]. It has been suggested that abnormal mem-
brane lipid compositions, namely decreases in the ratio
of Pl to non-Pl ethanolamine glycerophospholipids,
cause membrane instability in AD, which may contribute

























































































































Figure 5 Increases in the levels of IL-1β and TNF-α mRNAs
following LPS (i.p.) injection and suppression by Pls in the
murine PFC and hippocampus. A, Significant increases in the
levels of IL-1β (left) and TNF-α (right) mRNAs in the PFC were seen
in the LPS group compared with that observed in the other groups
(Con, LPS + Pls and Pls groups). B, Significant increases in the levels
of IL-1β (left) and TNF-α (right) mRNAs in the hippocampus were
seen in the LPS group compared to that observed in the other
groups. Each bar, n = 5, **, P <0.01. _Con, control; IL-1β,
interleukin-1β; i.p., intraperitoneal; LPS, lipopolysaccharide; PFC,
prefrontal cortex; Pls, plasmalogens; TNF-α, tumor necrosis factor α.
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cascade mechanisms [14]. Furthermore, since PlsEtn
are major endogenous lipid constituents that facilitate
membrane fusion of synaptic vesicles associated with
neurotransmitter release [31,32], pathological and/or
age-related alterations in the Pl levels may be attributed
to neurological disorders including AD [7]. In accor-
dance with this, it has been reported that decreases in
the amount of Pls are closely correlated with the severity
of dementia in humans [18,19].
Neuroinflammation-Aβ-Pls loop
There seems to be a causes/consequences loop involving
neuroinflammation that includes cytokine and ROS/RNS
production, Aβ accumulation and decreases in the
amount of Pls. LPS-induced activation of β-secretase [1],
which is predominantly localized in cholesterol-rich lipid
rafts [33,34], causes accumulation of Aβ proteins. Aβ-
induced production of ROS/RNS that enhance lipid per-
oxidation [35,36] may decrease Pl levels, as mentioned
above. In addition, increases in Aβ, cytokines and ROS/
RNS reduce the expression of alkyl-dihydroxyacetone
phosphate-synthase, a rate-limiting enzyme for Pl de
novo synthesis, by inducing the dysfunction of
peroxisomes, where Pls are biosynthesized, resulting in
decreases in the Pl levels [37]. It has also been reported
that TNF-α down regulates another key enzyme in Pl
biosynthesis in peroxisomes, glycerol-3-phosphate-O-
acyltransferase [38], and up regulates myeloperoxidase,
which generates one of the reactive species, hypochlor-
ous acid (HOCl), in the brain, targeting Pls to be oxi-
dized [39]. Finally, Pls-PLA2, which degrades Pls to
release DHA or ARA from the sn-2 position of the gly-
cerol moiety, is possibly activated by ceramide produced
under inflammatory conditions, and contributes to the
loss of Pls in the brain [9,40].
It is well known that the generation and clearance of
Aβ are affected by cholesterol metabolism, as evidenced
by the identification of a variant gene of apolipoprotein
E, a cholesterol transporter, as a major genetic risk factor
for AD [26,41,42]. It has been shown that decreases in
the amount of Pls induce a decreased rate of intracellu-
lar cholesterol transport from cell membranes to the
endoplasmic reticulum, which increases the cholesterol
levels in cell membranes [43]. Mankidy et al. further
indicated that esterification of cholesterol, an obligate
step that occurs prior to efflux from cells, is dependent
upon the amount of polyunsaturated fatty acid (PUFA)-

















Figure 6 Accumulation of Aβ proteins following LPS (i.p.) injection and suppression by Pls in the murine PFC. Neurons were stained with
NeuN (red). A weak fluorescence for Aβ3–16 immunoreactivity (green) in the Con group (b) increased following LPS treatment (e) and was
completely abolished by Pl administration (h). The Aβ3–16 fluorescence merged with the NeuN immunoreactivity, indicating the intracellular
localization of Aβ (f). Scale bar: 50 μm. Aβ, β-amyloid; Con, control; i.p., intraperitoneal; LPS, lipopolysaccharide; PFC, prefrontal cortex; Pls,
plasmalogens.
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increasing levels of the membrane-bound cholesterol-
processing enzyme, sterol-O-acyltransferase-1 [44].
Increases in the cholesterol levels promote the secretion
of Aβ [41,42,45], while depletion of cholesterol inhibits
the generation of Aβ [46,47]. Furthermore, it has been
shown that membrane Pls block cholesterol-mediated
increases in β-secretase activity and directly increase the
activity of α-secretase, which is known to promote non-
amyloidogenic processing of amyloid precursor proteins
[48]. Therefore, a vicious circle in which LPS-induced
Aβ accumulation decreases the Pl levels, which leads to
increased cholesterol levels, which further enhances the
generation of Aβ may be involved in the pathological
conditions of neuroinflammation.
Ameliorative effects of Pls on neuroinflammation
In the present study, we showed that LPS-induced acti-
vation of glial cells (Figures 2–4), expression of IL-1β
and TNF-α mRNAs (Figure 5), accumulation of Aβ pro-
teins (Figures 6 and 7) and decreases in the PlsEtn levels
(Table 2) in the PFC and hippocampus are all prevented
by co-administration of Pls. Although the precise
mechanisms underlying the effects of Pls in this study
are not known, supplementation with Pls could improve
pathological disorders. The most important question
may be whether peripheral Pls can enter into the brain.
So far, there are no reports indicating that Pls directly
cross the blood–brain barrier (BBB). Therefore, it is not
excluded that the anti-oxidative effects of Pls are exerted
outside the brain in order to suppress primary inflam-
mation induced by peripheral LPS. However, it has been
shown that the Pls levels in sera are decreased in parallel
with or even at earlier times than decreases in the brain
Pl levels in AD patients [18,19]. Furthermore, our results
showed that LPS-induced decreases in the Pls levels in
the PFC and hippocampus are corrected with peripheral
administration of Pls (Table 2). Therefore, it is possible
that peripheral supplementation with Pls would have
effects on the CNS by changing the Pl levels in the
brain.
Another question is whether the effective molecules in
our experiment are PUFAs, not Pls, which Pls must carry
at the sn-2 position. Several lines of evidence show that
n-3 PUFAs, such as eicosapentaenoic acid, DHA, and its
derivative, neuroprotectin D1, have anti-inflammatory
and neuroprotective effects [49-52]. Furthermore, DHA
has been reported to suppress the production of Aβ pro-

















Figure 7 Accumulation of Aβ proteins following LPS (i.p.) injection and suppression by Pls in the murine CA1 region of the
hippocampus. Neurons were stained with NeuN (red). A weak fluorescence for Aβ3–16 immunoreactivity (green) in the Con group (b) increased
following LPS treatment (e) and was markedly attenuated by Pl administration (h). The Aβ3–16 fluorescence merged with the NeuN
immunoreactivity, indicating the intracellular localization of Aβ (f and i). Scale bar: 50 μm. Aβ, β-amyloid; Con, control; i.p., intraperitoneal; LPS,
lipopolysaccharide; Pls, plasmalogens.
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of β-/γ-secretase activities and alteration of membrane
cholesterol distribution [53-55]. Since the purified Pls
used in the present study contained DHA and its precur-
sor, α-linolenic acid, especially in PlsEtn (Table 1), it can-
not be excluded that DHA derived from PlsEtn plays a
significant role in the CNS effects of Pls. Indeed, it has
been shown that DHA is synthesized from α-linolenic
acid and incorporated into phospholipids in the liver
then transported to the brain through the peripheral cir-
culation [56]. On the other hand, it has also been shown
that lyso-type phospholipids, which contain DHA at the
sn-2, show preferential transfer over DHA in in vitro
models of the BBB [57]. Furthermore, it has been sug-
gested that specific transport mechanisms to import Pls
and their synthetic precursors exist in brain capillary epi-
thelial cells [58,59]. These findings suggest that Pls con-
taining DHA exert more effective actions in the CNS
than DHA alone.
The present study suggests that co-administration of
Pls suppresses systemic LPS-induced neuroinflammation
in the brain. Although further studies on the mechan-
isms underlying these CNS effects, including the metab-
olism of the administered Pls and the pathways used to
enter the brain, are needed, the present results indicate
that Pls may possibly be used in new preventive and
therapeutic strategies for treating AD.
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